Addressing inflammatory arthritis, Ankylosing Spondylitis Treatment companies focus on providing effective therapies. Through research and development, they offer treatments that manage symptoms and slow disease progression, improving the quality of life for individuals affected by ankylosing spondylitis.
Lynk Therapeutics Announces Positive Phase 2b Results for LNK01001: This October 2023 news reported significant efficacy and favorable safety profile for LNK01001, a novel JAK1 selective inhibitor, in treating AS patients. Phase 3 trials are expected to begin soon.
Novartis Launches Phase 3 Trial for Cosentyx in Non-radiographic Axial Spondyloarthritis: This November 2023 development expands the potential reach of Cosentyx, a biologic already approved for AS, to patients with non-radiographic forms of the disease.
AbbVie Initiates Phase 2 Trial for Upadacitinib in Ankylosing Spondylitis: This January 2024 announcement strengthens AbbVie's presence in the AS market with a potential new JAK inhibitor option.
FDA Approves Intravenous Cosentyx for Ankylosing Spondylitis: This June 2023 approval offers a new administration option for Cosentyx, potentially improving convenience and compliance for some patients.
Expansion of Biosimilar Options for Existing Drugs: Increased availability of biosimilars for TNF-alpha inhibitors like Remicade and Humira could increase treatment access and potentially reduce costs.
Ankylosing Spondylitis Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)